[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinical Hospital Centre Zagreb\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":188},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,76,109,136,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100628013","phase-4-a-comparison-of-remimazolam-besylate-and-propofol-sedation-in-patients-undergoing-colonoscopic-polypectomy-100628013",false,"NCT07456111","A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy","Bypro","Inclusion Criteria:\n\n* Patients both male and female\n* ages 18 to 60 years,\n* with one or more colonic polyps confirmed by colonoscopy and scheduled for a colonoscopy and polypectomy\n* The duration of the colonoscopy ranges from 30 to 50 minutes.\n* ASA status (American Society of Anaesthesiologists physical status) I-III.\n* BMI (Body mass index) 18.5-29.9 kg\u002Fm2.\n* Only patients who signed an informed consent waiver and consented to participate in the research study.\n\nExclusion Criteria:\n\n* Patients aged \\>60 years\n* ASA status IV-V,\n* BMI \\>29.9 kg\u002Fm2,\n* a high risk of vomiting, regurgitation and\u002For aspiration of gastric contents.\n* Patients with:\n* uncontrolled hypertension (systolic pressure \\>160 mmHg),\n* heart disease (cardiomyopathy, cardiac-rhythm disorder, left ventricular ejection fraction \\\u003C45%, stenosis or heart valve insufficiency and coronary heart disease)\n* lung disease (pneumonia, chronic obstructive pulmonary disease, asthma and pulmonary tumors),\n* kidney diseases (kidney failure, GF 30\u002F59 ml\u002Fmin\u002F1.73m2),\n* liver diseases,\n* coagulation disorders\n* lymphatic tissue diseases\n* extended malignant disease.\n* History of allergy on nutritional allergens including soy bean, benzodiazepines, propofol or opioids.\n* Patients who currently use analgesic medications or other psycho-pharmaceuticals.\n* History of illicit drug use.\n* Children, pregnant and nursing women.\n* Alcohol dependency.\n* Patients involved in other clinical research studies,\n* patients who refused to take part in the research or have not signed the written informed consent form.","ALL","18 Years","60 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this prospective, randomized, controlled study is to compare remimazolam besilat\u002Fsufentanyl and propofol\u002Fsufentanyl in patients during colonoscopic polypectomies procedures.\n\nPatients undergoing colonoscopic polypectomies in procedural sedation using remimazolam besylate\u002Fsufentanyl are circulatory and respiratory as or more stable when compared with propofol\u002Fsufentanyl sedation.",[27,28],"Colonic Polyp","Sedation Complication",[30,31,32,33,34,35,36],"Remimazolam besylate","Propofol","Procedural sedation","Polypectomy","Circulatory stability","Respiratory stability","Respiratory depression","RECRUITING","2026-03-03",{"date":40,"type":41},"2026-03-06","ACTUAL",{"date":43,"type":41},"2025-01-01",{"date":45,"type":21},"2028-12-30",{"name":47,"class":48},"Clinical Hospital Centre Zagreb","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100622532","the-role-of-transcutaneous-vagus-nerve-stimulation-in-treatment-of-acute-brain-injury-100622532","NCT07384845","The Role of Transcutaneous Vagus Nerve Stimulation in Treatment of Acute Brain Injury","The Role of Transcutaneous Vagus Nerve Stimulation in Neuroprotection and the Reduction of the Systemic Inflammatory Response in Acute Brain Injury","IInclusion Criteria:\n\nPatients over 18 years of age with a diagnosis of traumatic brain injury or acute subarachnoid hemorrhage due to rupture of an intracranial aneurysm, confirmed by brain CT or MRI.\n\nExclusion Criteria:\n\nPatients under 18 years of age; patients with autoimmune diseases or malignant diseases; pregnant women; and patients for whom informed consent to participate in the study is not obtained.",{"count":58,"type":21},60,[60],"NA","Acute brain injury is a major global health problem associated with high mortality and morbidity, limited therapeutic options, prolonged hospital stays, and long-term disability that significantly impairs quality of life and increases healthcare costs. Noninvasive transcutaneous VNS developed as a safer approach for treating cerebral edema, epileptic seizures, and blood-brain barrier disruption, for facilitating the recovery of motoric and cognitive functions, and for immunomodulation.\n\nTranscutaneous VNS improves cerebral perfusion pressure and tissue oxygenation, supports reperfusion of the penumbral zone, and reduces neuronal hyperexcitability, thereby suppressing seizures.It may exert anti-inflammatory effects by reducing microglial cytokine and chemokine production. Additionally, vagal stimulation promotes acetylcholine-mediated suppression of pro-inflammatory cytokines, including TNF, IL-1β, IL-6, and IL-18.\n\nAnother anti-inflammatory mechanism involves ghrelin, a peptide hormone whose serum levels increase under vagal stimulation. Elevated ghrelin reduces TNF-α and other pro-inflammatory cytokines and may limit intracerebral hemorrhage by inhibiting the NLRP3 inflammasome and activating the Nrf2\u002FARE signaling pathway. Biomarkers such as S100 protein and neuron-specific enolase (NSE) are valuable indicators of brain tissue damage and clinical outcomes; tVNS may reduce their levels and support non-invasive monitoring of disease progression.\n\nThe technique is considered safe in patients .\n\nTo date, tVNS has not been evaluated in clinical trials in Croatia, nor reported in case studies or cohort analyses. Study outcomes will be correlated with patients' clinical status, duration and course of hospitalization, complication rates, and overall treatment outcomes.",[63,64,65,66],"Acute Brain Injury","Transcutaneous Vagus Nerve Stimulation","Neuromodulation","Immunomodulation","NOT_YET_RECRUITING","2026-01-26",{"date":70,"type":41},"2026-02-03",{"date":72,"type":21},"2026-02",{"date":74,"type":21},"2028-02",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100549918","phase-4-therapeutic-options-for-crab-100549918","NCT06440304","Therapeutic Options for CRAB","Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol","TheraCRAB","Inclusion Criteria:\n\n* Surgical patients (abdominal, vascular, and polytraumatized patients)\n* Older than 18 years\n* Require postoperative treatment in the ICU\n* A positive sample (surveillance or diagnostic) for A. baumannii with signs of systemic infection\n\nInfection will be defined as a diagnostic microbiologically positive sample for A. baumannii and a surveillance microbiologically positive sample for A. baumannii with signs of systemic infection (elevated CRP, leukocytes, and body temperature).\n\nColonization will be defined as a positive surveillance microbiological sample for A. baumannii in the absence of signs of systemic infection (normal CRP, leukocytes, and body temperature).\n\nExclusion Criteria:\n\n* Allergy to the study medications\n* Positive surveillance swabs for A. baumannii without signs of systemic infection\n* Positive findings (surveillance or diagnostic) for carbapenem-sensitive A. baumannii\n* Refusal to participate in the research","90 Years",{"count":86,"type":21},108,[24],"CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall.\n\nCurrent treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides (Amikacin, Gentamicin), which are limited by resistance, and tetracyclines (Tigecycline, Eravacycline), which are effective against CRAB. Fosfomycin is effective in combination treatments, and combination therapy (e.g., colistin with sulbactam, fosfomycin, or eravacycline) can enhance outcomes.\n\nPrevious research shows promise for combination therapies, improving treatment efficacy and reducing mortality. New regimens are being studied to find optimal combinations. Individualized dosing is crucial, considering patient-specific factors like age, weight, and renal function. Adjustments depend on the infection site and comorbidities.\n\nStrict infection control and antimicrobial stewardship programs (ASPs) are essential. ASPs focus on optimizing antibiotic use and reducing resistance through education and surveillance. Future directions include continued research for new drugs or combinations and strategies to overcome resistance and improve treatment efficacy.\n\nStudy goals include achieving negative samples after 10 days of therapy, 30-day survival, discharge rates, reduced SOFA scores, and improved clinical and radiological findings. A randomized study will compare colistin combined with fosfomycin, ampicillin\u002Fsulbactam, and eravacycline.\n\nIn summary, treating CRAB infections is complex, requiring combination therapy, individualized dosing, and strict infection control measures.",[90,91],"Infections, Bacterial","Sepsis Bacterial",[93,94,95,96,97,98,99,100],"Carbapenem-resistant Acinetobacter baumannii (CRAB)","Intensive Care Unit (ICU) infections","Polymyxins (colistin)","Combination antimicrobial therapy","Antimicrobial resistance mechanisms","Fosfomycin","Eravacyclin","Ampicillin\u002Fsulbactam","2026-01-16",{"date":103,"type":41},"2026-01-21",{"date":105,"type":41},"2025-01-30",{"date":107,"type":21},"2027-02",{"name":47,"class":48},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":49},"100537227","differences-in-speed-of-recovery-from-anesthesia-for-intraoral-surgery-100537227","NCT06275087","Differences in Speed of Recovery From Anesthesia for Intraoral Surgery","Differences in Speed of Recovery From Anesthesia and Recovery of Muscle Strength in General Balanced Inhalation Anesthesia and Total Intravenous Anesthesia for Intraoral Surgery - Clinical Randomised Trial","PSIOS","Criteria for patient inclusion are:\n\n* patients older than 18 years\n* ASA status 1-2,\n* Patients who have an indication for an intraoral surgical procedure longer than 30 minutes.\n* Surgical interventions on the soft tissues of the mouth, intraoral excision of tumors, operated through the transoral route\n* Patients who agreed to the research and signed the consent\n\nThe exclusion criteria are:\n\n* ASA status 3 and higher,\n* The need for postoperative care in the ICU,\n* Surgery lasting more than 2 hours,\n* Surgical procedures that in the operative plan include injuries to the grip of the masticatory muscles, the masticatory muscles themselves, and procedures on the bone, and thus may result in a difference in the strength of the bite. Masticatory muscles are defined as musculus pterygoideus lateralis, musculus pterygoideus medialis, musculus temporalis and musculus masseter.\n* Surgical procedures on the bone where the bite force test alone could cause injury\n* Patients with diseases of the neuromuscular junction and muscle diseases, myopathy, dystrophy\n* Patients taking medications that can cause myopathy or muscle weakness\n* Known allergies to drugs used in the trial,\n* Refusing to participate",{"count":118,"type":21},42,[60],"The goal of this clinical trial is to compare two groups of patients going in general anesthesia for intraoral surgery, the first group TIVA with propofol and the second group inhalational with sevoflurane. The main questions it aims to answer are to asses speed and quality of recovery from general anesthesia.\n\nParticipants will fill out a questionnaire to evaluate the quality of recovery from anesthesia using the QoR-40 1h, 24h, and 30 days after waking up from anesthesia in comparison to the results of the same questionnaire before surgery. Also, the investigators will perform a hand grip and bite strength test on the patients after waking up from anesthesia in the operating room, after 1 hour in the recovery room, and after 24 hours compared to preoperative values.\n\nThe investigators will compare TIVA and Volatile groups to see if there are any differences in recovery seed, muscle strength recovery, postoperative nausea and vomiting, and shivering between groups.",[122],"Intraoral Tumor",[124,31,125,126,127],"TIVA","Intraoral surgery","Postoperative recovery","recovery of muscle strenght","2025-12-17",{"date":130,"type":41},"2025-12-24",{"date":132,"type":41},"2024-04-10",{"date":134,"type":21},"2026-07",{"name":47,"class":48},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100615466","endothelial-glycocalyx-and-inflammatory-response-changes-in-patients-with-acute-stroke-undergoing-mechanical-thrombectomy-100615466","NCT07292974","ENDOTHELIAL GLYCOCALYX AND INFLAMMATORY RESPONSE CHANGES IN PATIENTS WITH ACUTE STROKE UNDERGOING MECHANICAL THROMBECTOMY","DYNAMIC CHANGES OF ENDOTHELIAL GLYCOCALYX AND INFLAMMATORY RESPONSE IN PATIENTS WITH ACUTE STROKE TREATED WITH MECHANICAL THROMBECTOMY","DEGIMT","Inclusion Criteria: all patients older than 18 years with a diagnosis of acute IS confirmed by brain CT or MRI, and to whom MT will be performed, regardless of whether they are previously received thrombolysis.\n\nExclusion Criteria: patients under the age of 18, patients with diagnosed with hemorrhagic stroke, patients with acute infection, autoimmune illness, malignant disease, trauma, pregnant women or patients who will refuse to participate in research.",true,{"count":146,"type":21},150,"2 Days","OBSERVATIONAL","Ischemic stroke (IS) is one of the leading causes of mortality and disability. Treatment of IS is based on reperfusion methods, thrombolysis and mechanical thrombectomy (MT). However, there are significant limitations in their implementation and success. Also, there is a mismatch between successful recanalization of the blood vessel, recovery of the neurological status as well as treatment outcome. Precisely for these reasons, there is a need for a better understanding of pathophysiology events in the acute IS and for the development of new therapeutic procedures that would include neuroprotection, modification of the inflammatory response and preservation of the integrity of the blood-brain barrier. Acute IS occurs as a result of a blood vessel blockage, which leads to ischemic damage to the brain parenchyma. It causes an early inflammatory response that is extremely complex, involving a large number of inflammatory cytokines whose dynamics and role in the pathophysiology of IS are insufficiently investigated. It is known that inflammatory processes damage the endothelial glycocalyx (EG), a thin luminal layer of the endothelium that has numerous functions such as maintaining the integrity of blood vessels and regulating tone, and itself participates in the inflammatory response. In the brain, EG is a key regulator of the integrity of the blood-brain barrier, and its damage makes the barrier more permeable, which can lead to edema and the passage of potentially harmful substances. Clinical studies have shown that there is a possible relationship between the prognosis of patients with IS and the concentration of EG breakdown products in the peripheral blood. However, the relationship between changes in EG and the inflammatory process in the context of IS, and especially in relation to available treatment methods, remains unclear. The aim of the proposed study is to determine and analyze the dynamics of concentrations of EG degradation products and inflammatory cytokines in patients with acute IS during and after MT. This study would include all adult patients with acute IS who will undergo MT, and the concentrations of EG degradation products and inflammatory cytokines would be determined by the enzyme immunoassay method from peripheral blood and blood samples from the cerebral circulation after reperfusion. The obtained results will be correlated with the collected data on the neurological condition of the patient before and after the intervention, the type and course of the intervention performed, the course and duration of hospital treatment, the occurrence of complications and the outcome of treatment.",[151,152,153],"Stroke","Thrombectomy","Endothelial Glycocalyx","2025-12-05",{"date":156,"type":41},"2025-12-18",{"date":158,"type":21},"2026-01",{"date":160,"type":21},"2030-10",{"name":47,"class":48},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100536533","impact-of-coronary-sinus-flow-reducer-on-coronary-microcirculation-and-myocardial-ischemia-100536533","NCT06266065","Impact of Coronary Sinus Flow Reducer on Coronary Microcirculation and Myocardial Ischemia","Impact of Coronary Sinus Flow Reducer on Coronary Microcirculation and Myocardial Ischemia in Patients With Refractory Angina Pectoris","Inclusion Criteria:\n\n* Patients with coronary artery disease and refractory angina pectoris who are ineligible for coronary revascularization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severely reduced systolic ejection fraction of the left ventricle (EF \\\u003C 35 %)\n* Severe renal impairment (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2)\n* Severe chronic obstructive pulmonary disease (GOLD D)\n* Contraindication for application of papaverine or regadenoson",{"count":170,"type":21},25,[60],"The increasing number of coronary revascularization procedures, coupled with improvements in drug therapy, has significantly extended the lifespan of patients with coronary artery disease (CAD). However, there remains a significant number of CAD patients who experience disability due to chronic refractory angina pectoris. These patients typically have severe diffuse CAD and are not candidates for further revascularization involving surgical coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).\n\nThe installation of a coronary sinus reducer (CSR) represents a new option for percutaneous treatment of patients with refractory angina pectoris who are not suitable for surgical or percutaneous revascularization. The CSR device is designed as an hourglass-shaped stent that is positioned transcatheterally in the distal part of the coronary sinus. This increases intramyocardial venous pressure, which is believed to lead to a more favorable perfusion ratio between the ischemic subendocardial and non-ischemic subepicardial myocardium. Previous research has demonstrated that the implantation of CSR is a safe and relatively straightforward procedure. However, broader implementation and better patient selection are still limited by the fact that the exact mechanism of action remains controversial. It has not been determined why some patients have better outcomes compared to others with seemingly similar coronary artery disease. It is known that patients with atherosclerotic changes in the epicardial coronary arteries also have a certain degree of coronary microcirculation disease (the coronary vascular bed encompassing vessels with a diameter \\\u003C 200 μm), which cannot be assessed through standard coronary angiography. This study aims to assess changes in coronary microcirculation after the implantation of CSR by measuring coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) before and 6 months after the procedure. Furthermore, our goal is to associate these changes with clinical symptoms and myocardial ischemia.",[174,175],"Coronary Artery Disease","Angina Pectoris",[177,178,179],"Coronary Sinus Reducer","Myocardial Ischemia","Coronary Microcirculation","2024-03-05",{"date":182,"type":41},"2024-03-06",{"date":184,"type":41},"2024-02-27",{"date":186,"type":21},"2026-06",{"name":47,"class":48},""]